Nurix Therapeutics
Develops protein-degradation medicines through DEL-AI and large-pharma collaborations.
Something off on this page? Send us feedback.
Profile
Develops targeted protein degradation medicines for cancer, inflammatory disease, and other indications through DEL-AI. Revenue is collaboration-based rather than product-based, with Roche, Gilead, Sanofi, and Pfizer shaping the pipeline and funding model.
Develops targeted protein degradation therapies through DEL-AI, a discovery platform built around E3 ligases and small-molecule modulation of cellular proteins. The main clinical programs are bexobrutideg, zelebrudomide, and NX-1607, alongside partnered IRAK4, STAT6, and DAC programs.
Operations are concentrated in Brisbane, California, with a research-heavy employee base and outsourced clinical trial and manufacturing work. Bexobrutideg moved into pivotal development for relapsed or refractory CLL and is now co-developed with Roche across malignant hematology, immunology, and neurology.
The business has no approved product revenue in the context reviewed. Collaboration economics with Roche, Gilead, Sanofi, and Pfizer, clinical trial outcomes, manufacturing partners, and competition from protein degradation and other therapeutic modalities shape the operating model.
Company facts
Key statistics
Year to date +45.0% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 28, 2026 | Morgan Stanley | Reiterate | Overweight | $36 | $38 |
| Jul 22, 2026 | UBS | Reiterate | Buy | $23 | $31 |
| Jul 13, 2026 | Mizuho Securities | Target | $34 | ||
| Jul 10, 2026 | RBC Capital | Reiterate | Outperform | $29 | $33 |
| Jul 10, 2026 | Truist Financial | Target | $32 | $34 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026Q2 FY26 | −$0.73 | −$0.81 | −11.0% | $15.3M | $9.0M | −40.9% | −6.60% |
| Apr 8, 2026Q1 FY26 | −$0.76 | −$0.79 | −3.9% | $14.3M | $6.3M | −56.1% | +4.10% |
| Jan 28, 2026Q4 FY25 | −$0.84 | −$0.82 | +2.4% | $13.4M | $13.6M | +1.3% | −1.57% |
| Oct 9, 2025Q3 FY25 | −$0.84 | −$1.03 | −22.6% | $12.3M | $7.9M | −35.6% | −10.13% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $18.5M | $44.1M | $7.9M | $13.6M | $6.3M | $9.0M | |
| Gross profit | −$51.2M | −$34.0M | $2.9M | $8.9M | −$77.9M | $5.2M | |
| Operating income | −$62.9M | −$48.3M | −$91.4M | −$83.1M | −$92.5M | −$94.2M | |
| Net income | −$56.4M | −$43.5M | −$86.4M | −$78.2M | −$87.2M | −$89.5M | |
| Diluted EPS | −$0.67 | −$0.52 | −$1.03 | −$0.82 | −$0.79 | −$0.81 | |
| Gross margin | -277.5% | -77.3% | 36.7% | 65.9% | -1,245.8% | 57.4% | |
| Operating margin | -340.7% | -109.7% | -1,157.7% | -612.0% | -1,479.4% | -1,041.7% |
Fiscal years (4-quarter sums)FY21 $29.8M · FY22 $38.6M · FY23 $77.0M · FY24 $54.5M · FY25 $84.0M
Revenue by product · Q2 FY26
Balance sheet, May 31, 2026Cash & short-term investments $443.5M · Total debt $58.1M · Total assets $535.5M · Shareholders' equity $402.6M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 103.78M · Float 98.26M · 94.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 8.77M | 8.45% | 13F | Aug 7, 2026 |
| Vestal Point Capital, LP | 8.05M | 7.76% | 13F | Aug 14, 2026 |
| Deep Track Capital, LP | 7.74M | 7.45% | 13F | Aug 14, 2026 |
| Rubric Capital Management LP | 7.23M | 6.96% | 13G | Aug 14, 2026 |
| FMR LLC | 5.49M | 5.29% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −4,111 | $24.36 |
| Aug 5, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −4,356 | $25.00 |
| Aug 4, 2026 | Hans van Houte | officer: Chief Financial Officer | −4,761 | $24.36 |
| Aug 3, 2026 | Christine Ring | officer: Chief Legal Officer | −16,589 | $23.05 |
| Jul 30, 2026 | Gwenn Hansen | officer: Chief Scientific Officer | −3,847 | $23.38 |
Peers
- BeOne Medicines (ADR)
BTK inhibitor and degrader pressure in B-cell malignancies
- Eli Lilly
Non-covalent BTK inhibitor pressure in relapsed CLL/SLL
- AstraZeneca (ADR)
Covalent BTK inhibitor standard in CLL/SLL and MCL
- Kymera Therapeutics
Oral degrader platform overlap in STAT6 and IRAK4 biology
- Arvinas
PROTAC platform peer with the first FDA-approved degrader
- AbbVie
Ibrutinib franchise and BTK-degrader pipeline overlap
- Monte Rosa Therapeutics
Molecular glue degrader peer in immunology and oncology
- C4 Therapeutics
Oncology TPD peer with IKZF1/3 and DAC programs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nurix Therapeutics | $26.64 | +1.72% | $2.72B | — | — | 74.0 | −79.5% |
| BeOne Medicines (ADR) | $366.73 | −0.01% | $39.19B | 5.1 | 46.7 | 6.9 | +29.6% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Kymera Therapeutics | $118.15 | +0.06% | $9.72B | — | — | 92.6 | +466.4% |
| Arvinas | $9.18 | +0.05% | $592.3M | 57.4 | — | 1.9 | +1,014.7% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Monte Rosa Therapeutics | $13.38 | +0.04% | $1.13B | — | — | 39.3 | −61.2% |
| C4 Therapeutics | $3.91 | +1.54% | $425.7M | — | — | 12.1 | +2.8% |
| Median | 39.4 | 22.8 | 9.6 | +19.9% |